MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
CODICE STUDIO
NCT06152575
TIPOLOGIA
Ricaduti
NOME SPONSOR
Pfizer
DESCRIZIONE
Trattamento
Participant Group/Arm
Experimental: Elranatamab
Participants will receive elranatamab monotherapy
Active Comparator: Investigator’s Choice
Participants will receive either Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd)
Intervention/Treatment
Drug: Elranatamab
• Elranatamab will be administered subcutaneously
Drug: Elotuzumab
• Elotuzumab will be administered intravenously
Drug: Pomalidomide
• Pomalidomide will be administered orally
Drug: Dexamethasone
• Dexamethasone will be administered orally
Drug: Bortezomib
• Bortezomib will be administered subcutaneously or intravenously
Drug: Carfilzomib
• Carfilzomib will be administered intravenously
FARMACI UTILIZZATI